OverviewSuggest Edit

Oncorus is a biopharmaceutical company focused on developing viral immunotherapies to transform outcomes for cancer patients. Using its two platforms, the company develops a pipeline of intratumorally and intravenously administered product candidates designed to selectively attack and kill tumor cells and stimulate multiple arms of the immune system against tumors.

TypePublic
Founded2015
HQCambridge, MA, US
Websiteoncorus.com
Overall CultureF

Latest Updates

Employees (est.) (Sept 2020)51(-3%)
Share Price (Feb 2021)$23.9
Cybersecurity ratingBMore

Key People/Management at Oncorus

Ted Ashburn

Ted Ashburn

President & CEO, Director
John McCabe

John McCabe

Chief Financial Officer
Mitchell H. Finer

Mitchell H. Finer

Executive Chairman
Christophe Quéva

Christophe Quéva

Chief Scientific Officer and Senior Vice President of Research
Lorena Lerner

Lorena Lerner

Vice President of Molecular Biology
Stephanie Duncanson

Stephanie Duncanson

Senior Director of Corporate Strategy and Business Development
Show more

Oncorus Office Locations

Oncorus has an office in Cambridge
Cambridge, MA, US (HQ)
50 Hampshire St #401
Show all (1)

Oncorus Financials and Metrics

Oncorus Revenue

USD

Net income (H1, 2020)

(17.2m)

EBIT (H1, 2020)

(16.7m)

Market capitalization (8-Feb-2021)

539.4m

Closing stock price (8-Feb-2021)

23.9

Cash (30-Jun-2020)

28.9m
Oncorus's current market capitalization is $539.4 m.
Annual
USDFY, 2018FY, 2019

General and administrative expense

6.0m7.1m

R&D expense

12.5m24.0m

Operating expense total

18.6m31.2m

EBIT

(18.6m)(31.2m)
Half Year
USDH1, 2019H1, 2020

General and administrative expense

2.5m4.1m

R&D expense

12.0m12.6m

Operating expense total

14.4m16.7m

EBIT

(14.4m)(16.7m)
Annual
USDFY, 2018FY, 2019

Cash

20.1m45.3m

Current Assets

20.9m45.9m

PP&E

4.3m4.5m

Total Assets

25.7m50.8m
Quarterly
USDQ2, 2020

Cash

28.9m

Current Assets

30.6m

PP&E

4.8m

Total Assets

35.8m
Annual
USDFY, 2018FY, 2019

Net Income

(18.0m)(30.7m)

Depreciation and Amortization

956.0k1.1m

Cash From Operating Activities

(17.2m)(27.2m)

Purchases of PP&E

(291.0k)(977.0k)
Quarterly
USDQ2, 2019Q2, 2020

Net Income

(14.3m)(17.2k)

Depreciation and Amortization

519.0k628.0k

Cash From Operating Activities

(11.0m)(15.6m)

Purchases of PP&E

(118.0k)(747.0k)
USDFY, 2018

Financial Leverage

-0.6 x
Show all financial metrics

Oncorus Operating Metrics

Q2, 2020

Research Stage Products

3

Phase I Trials Products

1

Patents (US)

15

Patents (Foreign)

11
Show all operating metrics

Oncorus Acquisitions / Subsidiaries

Company NameDateDeal Size
Oncorus Securities Corporation

Oncorus Cybersecurity Score

Cybersecurity ratingPremium dataset

B

87/100

SecurityScorecard logo

Oncorus Online and Social Media Presence

Embed Graph

Oncorus Company Culture

  • Overall Culture

    F

    34/100

  • CEO Rating

    F

    30/100

  • Compensation

    F

    10/100

Learn more on Comparably

Oncorus News and Updates

Oncorus Announces Publication of Preclinical Data Demonstrating Potent Systemic Antitumor Activity of its Clinical Stage Oncolytic Herpes Simplex Viral Immunotherapy Product Candidate ONCR-177

-- Preclinical findings show that ONCR-177’s systemic antitumor immunity is driven by its five complementary immunomodulatory transgene payloads and retention of γ34.5 -- -- Complete and durable tumor regression and protective antitumor memory observed in multiple syngeneic tumor models --

Oncorus Appoints Scott Canute to its Board of Directors

-- Former Genzyme and Lilly executive brings broad industry expertise as Oncorus advances its viral immunotherapies pipeline and plans strategic operations and manufacturing scale-up -- -- Former Genzyme and Lilly executive brings broad industry expertise as Oncorus advances its viral immunotherapie…

Oncorus Appoints Steve Harbin as Chief Operating Officer and Chief of Staff

-- Former Moderna executive and industry veteran brings diverse operational expertise as Oncorus plans buildout of its manufacturing capabilities to support its viral immunotherapy pipeline -- -- Former Moderna executive and industry veteran brings diverse operational expertise as Oncorus plans buil…

Oncorus to Participate in Fireside Chats at Upcoming Piper Sandler Annual Healthcare Conference and Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq:ONCR), a viral immunotherapies company focused on driving innovation to transform outcomes for cancer patients, announced today that Theodore (Ted) A. Asbhurn, M.D., Ph.D., President and Chief Executive Officer, will partici…

Oncorus Reports Third Quarter 2020 Financial Results and Provides Business Highlights

-- Received $98.4 million in aggregate gross proceeds in October from initial public offering -- -- Initiated Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the treatment of solid tumors --

Oncorus to Present at Chardan 4th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company focused on developing next-generation viral immunotherapies to transform outcomes for cancer patients, today announced that its President and Chief Executive Officer, Theodo…
Show more

Oncorus Frequently Asked Questions

  • When was Oncorus founded?

    Oncorus was founded in 2015.

  • Who are Oncorus key executives?

    Oncorus's key executives are Ted Ashburn, John McCabe and Mitchell H. Finer.

  • How many employees does Oncorus have?

    Oncorus has 51 employees.

  • Who are Oncorus competitors?

    Competitors of Oncorus include Invectys, Alpine Immune Sciences and Incanthera.

  • Where is Oncorus headquarters?

    Oncorus headquarters is located at 50 Hampshire St #401, Cambridge.

  • Where are Oncorus offices?

    Oncorus has an office in Cambridge.

  • How many offices does Oncorus have?

    Oncorus has 1 office.